Skip to main content

Ganesan Vaidyanathan

Professor Emeritus in Radiology
Radiology
Box 3808 Med Ctr, Radiology, Durham, NC 27710
161C Bryan Res Bldg, Durham, NC 27710

Selected Grants


Targeted Radiolabeled PARP inhibitors (PARPi) -Site-specific radiolabeling

ResearchPrincipal Investigator · Awarded by Zentera Alpha, Inc · 2022 - 2026

PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo Investigator · Awarded by National Institutes of Health · 1985 - 2021

Labeling nanobodies with 18F residualizing labels for HER2 specific PET imaging

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2021

Cereius research agreement

ResearchPrincipal Investigator · Awarded by Cereius Inc. · 2017 - 2019

Targeted Radiolabeled PARP inhibitors (PARPi) -Site-specific radiolabeling

ResearchPrincipal Investigator · Awarded by Zentera Alpha, Inc · 2022 - 2026

PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo Investigator · Awarded by National Institutes of Health · 1985 - 2021

Labeling nanobodies with 18F residualizing labels for HER2 specific PET imaging

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2021

Cereius research agreement

ResearchPrincipal Investigator · Awarded by Cereius Inc. · 2017 - 2019

Novel Radiohalogenation Strategies for Enhancing Imaging and Targeted Radiotherapy with Ultrasmall Dual- Modality Silica Nanoparticles (C Dots)

ResearchCo-Principal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2016 - 2018

Development of a Targeted Radionuclide Therapy for Triple Negative Breast Cancer

ResearchPrincipal Investigator · Awarded by OncoTAb, Inc. · 2016 - 2017

Research Training In Neuro-Oncology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1998 - 2016

Enhancing the efficacy of targeted radiotherapy for neuroblastoma

ResearchPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2013 - 2014

Cross-disciplinary Training in Medical Physics

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2007 - 2013

Brain Tumors - Immunological and Biological Studies

ResearchInvestigator · Awarded by National Institutes of Health · 2001 - 2013

Small Animal PET / CT Molecular Imaging

EquipmentMajor User · Awarded by National Institutes of Health · 2011 - 2012

Radionuclide-based Molecular Imaging of the DNA Repair Protein AGT

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2011

Astatine-211 Radiochemistry: The Development of Methodologies for High Activity Level Radio-Synthesis

ResearchCo Investigator · Awarded by Department of Energy · 2008 - 2010

Research Training In Neuro-Oncology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2005 - 2010

Imaging of O6-Alkylguianine-DNA Alkyltransferase

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2007

Targeted Radiotherapeutics: Chemical and Biological Aspects

ResearchInvestigator · Awarded by Department of Energy · 2004 - 2006

Astatine-211 & Radioiodine Labeled Octreotide Conjugates

ResearchAssociate in Research · Awarded by National Institutes of Health · 2001 - 2006

Anti-Tenascin Antibody Constructs

ResearchCo Investigator · Awarded by Department of Energy · 1995 - 2005

Molecular Imaging Center Planning Grant

ResearchProject Leader · Awarded by National Institutes of Health · 2000 - 2004

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1999 - 2004

MIBG Analogue Radiopharmaceuticals

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2003

Brain Tumors--Immunological and Biological Studies

ResearchInvestigator · Awarded by National Institutes of Health · 1976 - 2001

Brain Tumors - Immunological And Biological Studies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1997 - 1999

Src On Primary And Matastatic Tumors Of The Cns

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1994 - 1999

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1994 - 1999

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1993 - 1999

Astatine And Iodine Radiolabeled Monoclonal Antibodies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1985 - 1999

Positron Emission Imaging Of Tumors Using Monoclonal Antib

ResearchCo-Principal Investigator · Awarded by Department of Energy · 1995 - 1998

Migb And Analogs For Diagnosis And Therapy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1994 - 1998

Mibg And Analogs For Diagnosis And Therapy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998

Mibg And Analogs For Diagnosis And Therapy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998

Migb And Analogs For Diagnosis And Therapy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998

Cancer And Leukemia Group B Statistical Center

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1992 - 1993

External Relationships


  • Cereius
  • Z-Alpha, Inc

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.